STEMI in Egypt: From Risk Factors to Reperfusion:An Updated Review of National Evidence

Moataz A. Elkot [1], Muhammad Wafaie Aboleineen [1], Ahmed Shawky Shereef [1], Basel Hatem Saadel Din Muhammad [2]
1 Department of Cardiology, Faculty of Medicine, Zagazig University
2 Department of Cardiology, National Heart Institute

Corresponding Author: Basel Hatem Saadel Din Muhammad

Received: 28 October 2024, **Accepted:** 17 November 2024, **Published:** 20 November 2024

Abstract

Background: ST-segment elevation myocardial infarction (STEMI) remains one of the leading causes of cardiovascular morbidity and mortality worldwide despite substantial advances in prevention, diagnosis, and reperfusion therapies. Significant regional variations exist in STEMI epidemiology, risk factor profiles, clinical presentation, treatment strategies, and outcomes. Egypt, as the most populous country in the Middle East and North Africa region, faces a substantial burden of cardiovascular disease, with STEMI representing a major public health challenge. Contemporary evidence suggests that Egyptian STEMI patients exhibit distinctive demographic and clinical characteristics compared with patients from Western countries, including younger age at presentation, higher prevalence of diabetes mellitus and smoking, delayed hospital presentation, and lower utilization of emergency medical services.

Aim: This review aims to comprehensively evaluate the epidemiology, risk factor distribution, clinical characteristics, contemporary management strategies, and outcomes of STEMI patients in Egypt. Furthermore, it explores current challenges within the Egyptian healthcare system and discusses future opportunities for improving STEMI care and reducing cardiovascular mortality.

Available evidence indicates that Egyptian STEMI patients frequently present at a younger age and carry a substantial burden of modifiable cardiovascular risk factors, particularly smoking and diabetes mellitus. Delayed symptom recognition, prolonged total ischemic time, limited utilization of ambulance services, and disparities in access to primary percutaneous coronary intervention (PCI) continue to affect treatment outcomes. Although considerable progress has been achieved through expansion of PCI-capable centers and implementation of guideline-directed therapies, thrombolytic therapy remains widely utilized in many regions. Recent national registry data have highlighted persistent gaps in reperfusion strategies and demonstrated higher in-hospital mortality among patients who do not receive timely reperfusion therapy. Emerging challenges include the increasing prevalence of obesity, metabolic syndrome, and diabetes mellitus, alongside population aging and healthcare resource constraints.

Conclusion: STEMI continues to impose a substantial clinical and socioeconomic burden in Egypt. Enhanced primary prevention programs, public awareness campaigns, improved emergency medical service utilization, expansion of regional STEMI networks, and equitable access to primary PCI are essential for optimizing patient outcomes. Future national initiatives focusing on early diagnosis, rapid reperfusion, and comprehensive secondary prevention may significantly reduce STEMI-related morbidity and mortality across Egypt.

.

Keywords: ST-Segment Elevation Myocardial Infarction, Epidemiology, Clinical Characteristics

Introduction

Cardiovascular disease remains the leading cause of death globally, accounting for approximately one-third of all deaths worldwide. Among cardiovascular diseases, ischemic heart disease (IHD) represents the most prevalent cause of mortality and disability-adjusted life years lost. Acute coronary syndrome (ACS), particularly ST-segment elevation myocardial infarction (STEMI), constitutes one of the most severe clinical manifestations of coronary artery disease and requires urgent recognition and reperfusion to preserve myocardial function and improve survival. Despite major advances in pharmacological therapies, coronary intervention techniques, and preventive cardiology, STEMI continues to contribute substantially to global healthcare expenditures and mortality rates, especially in low- and middle-income countries.[1,2]

The pathophysiological hallmark of STEMI is abrupt coronary artery occlusion, most commonly resulting from rupture or erosion of an atherosclerotic plaque followed by platelet aggregation and thrombus formation. The resulting interruption of coronary blood flow leads to progressive myocardial ischemia, irreversible myocardial necrosis, ventricular dysfunction, and potentially fatal complications if timely reperfusion is not achieved. Consequently, minimizing total ischemic time remains the cornerstone of contemporary STEMI management.[3,4]

Egypt faces a considerable burden of cardiovascular disease driven by rapid urbanization, population growth, increasing prevalence of diabetes mellitus, obesity, hypertension, dyslipidemia, and tobacco consumption. Several studies have demonstrated that Egyptian patients with STEMI differ from patients in many Western populations, often presenting at a younger age and exhibiting a higher prevalence of modifiable cardiovascular risk factors. Furthermore, healthcare-system-related challenges, including delayed hospital presentation, underutilization of emergency medical services, and variability in access to primary percutaneous coronary intervention (PCI), continue to influence patient outcomes.[5,6]

Although numerous international reviews have evaluated STEMI epidemiology and management globally, there remains a relative paucity of comprehensive reviews specifically focused on the Egyptian population. Most available data are derived from single-center experiences or registry-based analyses, and the existing evidence has not been comprehensively synthesized to provide an integrated overview of contemporary STEMI care in Egypt.[5,6]

Research Gap

Current literature lacks a dedicated, up-to-date review integrating epidemiological patterns, cardiovascular risk factors, clinical characteristics, reperfusion practices, treatment outcomes, and future healthcare challenges among Egyptian STEMI patients. Moreover, the rapidly evolving landscape of primary PCI networks and contemporary guideline-directed management warrants reassessment of available evidence.

Aim of the Review

This review aims to provide a comprehensive overview of STEMI in Egypt, focusing on epidemiology, cardiovascular risk profiles, clinical presentation, diagnostic approaches, contemporary management strategies, clinical outcomes, and future directions for improving STEMI care nationwide.

ST-segment elevation myocardial infarction (STEMI) remains one of the most important causes of cardiovascular morbidity and mortality worldwide. Although advances in preventive cardiology, public health interventions, and reperfusion therapies have resulted in declining STEMI incidence and mortality in many high-income countries, the burden of disease remains substantial in low- and middle-income countries. The Middle East and North Africa (MENA) region is currently experiencing an epidemiological transition characterized by increasing prevalence of cardiovascular risk factors, urbanization, aging populations, and lifestyle changes that contribute significantly to ischemic heart disease burden. Egypt, as the most populous country in the Arab world, represents a major contributor to the regional cardiovascular disease burden and faces unique challenges in STEMI prevention and management.[7,8]

Cardiovascular disease is the leading cause of death in Egypt and accounts for a considerable proportion of national mortality. Similar to other developing countries, Egypt has witnessed a marked increase in the prevalence of diabetes mellitus, obesity, hypertension, dyslipidemia, smoking, and sedentary lifestyle over recent decades. These epidemiological changes have been accompanied by increasing rates of coronary artery disease and acute myocardial infarction. The growing burden of cardiovascular disease places substantial pressure on healthcare resources and highlights the need for effective preventive and therapeutic strategies targeting STEMI and other manifestations of coronary artery disease.[8,9]

One of the most distinctive epidemiological features of STEMI in Egypt is the relatively young age at presentation compared with Western populations. Data from national and regional registries consistently demonstrate that Egyptian patients experience STEMI approximately 5–10 years earlier than patients in many European countries. Premature coronary artery disease is particularly important because it affects economically productive age groups and is associated with greater long-term socioeconomic consequences. Earlier onset of STEMI in Egypt is believed to be driven by the high prevalence of smoking, diabetes mellitus, metabolic syndrome, obesity, and other modifiable cardiovascular risk factors that develop at younger ages.[5,10]

The Egyptian Society of Cardiology conducted one of the largest national STEMI registries between 2016 and 2018 involving 19 cardiac centers with and without PCI capability across Egypt. This landmark study provided valuable insights into contemporary STEMI epidemiology and revealed significant differences between Egyptian patients and patients enrolled from other European Society of Cardiology (ESC) member countries. Egyptian STEMI patients were significantly younger and demonstrated a markedly higher prevalence of smoking and diabetes mellitus. These findings support the concept that Egypt is experiencing an accelerated cardiovascular risk profile that predisposes individuals to premature atherosclerotic disease and acute coronary events.[5]

Smoking represents one of the most influential epidemiological determinants of STEMI in Egypt. Tobacco use remains highly prevalent among Egyptian males and continues to be a major contributor to acute myocardial infarction. The high burden of smoking in Egyptian STEMI cohorts mirrors observations from several developing countries where tobacco control measures may be less effective than those implemented in many Western nations. The persistence of smoking as a dominant risk factor contributes significantly to the younger age of STEMI presentation and increases the risk of recurrent cardiovascular events following myocardial infarction.[5,11]

Diabetes mellitus is another defining epidemiological characteristic of STEMI in Egypt. Egypt is among the countries with the highest prevalence of diabetes globally, and this trend continues to rise because of increasing obesity rates, dietary changes, and reduced physical activity. Diabetes accelerates atherosclerosis, promotes endothelial dysfunction, increases thrombogenicity, and is associated with more diffuse coronary artery disease. Consequently, diabetic patients frequently present with more complex coronary lesions, higher rates of multivessel disease, and worse clinical outcomes after STEMI. The disproportionately high prevalence of diabetes among Egyptian STEMI patients distinguishes the Egyptian population from many Western cohorts and may partially explain observed differences in outcomes.[12,13]

Hypertension and dyslipidemia are also highly prevalent among Egyptian patients presenting with STEMI. These risk factors often coexist with diabetes and obesity, creating a synergistic effect that accelerates atherosclerotic progression. Recent epidemiological data indicate that metabolic syndrome has become increasingly common in Egypt, reflecting broader global trends related to urbanization and lifestyle modification. The clustering of multiple cardiovascular risk factors substantially increases the probability of premature coronary artery disease and recurrent ischemic events.[14,15]

Sex distribution in Egyptian STEMI populations demonstrates a predominance of male patients, a finding consistent with international STEMI registries. Men generally experience myocardial infarction at younger ages than women, partly because of differences in hormonal protection before menopause and higher prevalence of smoking among males. However, female STEMI patients often present at older ages and

may exhibit atypical symptoms, potentially contributing to delays in diagnosis and treatment. Recognition of sex-specific differences remains important for optimizing STEMI care and improving outcomes among women.[16]

Another notable epidemiological observation in Egypt is delayed hospital presentation following symptom onset. Timely reperfusion is the most important determinant of myocardial salvage and survival in STEMI. Nevertheless, many Egyptian patients continue to experience prolonged symptom-to-door times due to inadequate awareness of myocardial infarction symptoms, transportation challenges, socioeconomic barriers, and underutilization of emergency medical services. Delayed presentation reduces eligibility for optimal reperfusion therapies and contributes to increased infarct size, heart failure, arrhythmias, and mortality.[5,17]

The mode of hospital presentation differs substantially between Egypt and many developed healthcare systems. Registry data demonstrate that a large proportion of Egyptian STEMI patients arrive at healthcare facilities through self-transport rather than ambulance services. In contrast, emergency medical service activation is considerably more common in Europe and North America. Reduced ambulance utilization delays diagnosis, prehospital triage, and early initiation of reperfusion pathways. Strengthening emergency medical systems and increasing public awareness regarding ambulance activation represent important targets for improving STEMI outcomes nationwide.[5,18]

Reperfusion practices also provide valuable epidemiological insights into STEMI care within Egypt. Although primary percutaneous coronary intervention has become the preferred reperfusion strategy according to international guidelines, access remains variable across different regions. Urban centers and tertiary hospitals generally possess greater PCI capability, whereas thrombolytic therapy continues to play a major role in many peripheral and resource-limited settings. Consequently, reperfusion patterns in Egypt reflect both healthcare infrastructure disparities and geographic variation in access to specialized cardiovascular services.[4,5]

Comparison with international populations further highlights the unique epidemiological profile of Egyptian STEMI patients. Compared with European cohorts, Egyptians typically present at younger ages and exhibit higher rates of smoking and diabetes mellitus. Similar patterns have been observed in other Middle Eastern and South Asian populations, suggesting shared environmental, genetic, metabolic, and lifestyle influences. These regional differences emphasize the importance of tailoring prevention programs and healthcare policies to local epidemiological realities rather than relying solely on data derived from Western populations.[19,20]

Despite considerable progress in cardiovascular care, STEMI continues to be associated with substantial morbidity and mortality in Egypt. Registry data indicate that outcomes are strongly influenced by reperfusion status, treatment delays, and availability of contemporary guideline-directed therapies. Patients who do not receive timely reperfusion experience significantly higher mortality rates than those treated with primary PCI or effective thrombolysis. These observations underscore the critical importance of improving STEMI systems of care and expanding access to evidence-based interventions throughout the country.[5,17]

Future epidemiological trends suggest that Egypt may continue to face a growing burden of STEMI unless aggressive preventive measures are implemented. Increasing rates of obesity, diabetes mellitus, sedentary lifestyle, and population aging are likely to contribute to continued growth in coronary artery disease prevalence. National strategies emphasizing smoking cessation, cardiovascular risk factor control, public education, and expansion of STEMI networks will be essential for reducing disease burden and improving long-term cardiovascular health outcomes.[8,9]

Cardiovascular Risk Factors in Egyptian STEMI Patients

Cardiovascular risk factors are the primary drivers of ST-segment elevation myocardial infarction (STEMI) and represent the cornerstone of both primary and secondary prevention strategies. Understanding the distribution and impact of these risk factors within the Egyptian population is

particularly important because Egyptian patients frequently present with STEMI at a younger age than their counterparts in many Western countries. Evidence from Egyptian registries and regional studies consistently demonstrates a high prevalence of modifiable cardiovascular risk factors, including smoking, diabetes mellitus, hypertension, dyslipidemia, obesity, and sedentary lifestyle. The clustering of these risk factors contributes substantially to accelerated atherosclerosis, premature coronary artery disease, and adverse cardiovascular outcomes.[21,22]

Smoking

Smoking remains the most important preventable risk factor for STEMI in Egypt and is particularly prevalent among younger male patients. Numerous studies have established a strong association between cigarette smoking and acute myocardial infarction through multiple mechanisms including endothelial dysfunction, increased platelet aggregation, enhanced sympathetic activation, oxidative stress, inflammation, and coronary vasoconstriction. Smoking also promotes oxidation of low-density lipoprotein cholesterol (LDL-C), accelerates atherosclerotic plaque formation, and increases the likelihood of plaque rupture and thrombosis.[23,24]

The Egyptian STEMI registry demonstrated that smoking prevalence among Egyptian STEMI patients was significantly higher than that reported in many European cohorts. This finding is particularly important because smoking contributes to premature coronary artery disease and explains, in part, the younger age at STEMI presentation observed in Egypt. Similar observations have been reported throughout the Middle East and South Asia, where smoking remains a dominant cardiovascular risk factor among men. Importantly, smoking cessation after myocardial infarction substantially reduces recurrent cardiovascular events and mortality, emphasizing the need for aggressive smoking cessation interventions as part of secondary prevention programs.[20,25]

Beyond traditional cigarette smoking, increasing use of waterpipe tobacco (shisha) represents an emerging public health concern in Egypt and the wider Middle East. Many individuals incorrectly perceive waterpipe smoking as safer than cigarette smoking despite evidence demonstrating comparable or even greater exposure to nicotine, carbon monoxide, and toxic substances. Waterpipe smoking has been associated with endothelial dysfunction, increased arterial stiffness, and elevated cardiovascular risk, making it an important target for future preventive strategies.[26]

Diabetes Mellitus

Diabetes mellitus is among the most prevalent and clinically significant cardiovascular risk factors in Egyptian STEMI patients. Egypt is recognized as one of the countries with the highest burden of diabetes globally, reflecting increasing rates of obesity, urbanization, dietary changes, and reduced physical activity. Diabetes accelerates the atherosclerotic process through mechanisms involving endothelial dysfunction, oxidative stress, chronic inflammation, platelet activation, and vascular remodeling.[27,28]

The relationship between diabetes and cardiovascular disease is particularly strong. Previous studies have demonstrated that diabetic individuals have a cardiovascular risk equivalent to aging by approximately 15 years compared with non-diabetic individuals. Furthermore, diabetes is associated with a two- to eight-fold increase in cardiovascular events and remains responsible for the majority of deaths among diabetic patients. Coronary artery disease accounts for approximately three-quarters of mortality among patients with diabetes mellitus.[29]

Among Egyptian STEMI populations, diabetes prevalence is consistently higher than that observed in many European cohorts. Diabetic patients often present with more diffuse coronary artery disease, multivessel involvement, impaired collateral circulation, and greater plaque burden. They also experience higher rates of heart failure, recurrent myocardial infarction, and mortality following STEMI. Additionally, diabetic patients may present with atypical symptoms or silent ischemia, potentially delaying diagnosis and reperfusion therapy.[20,27]

The increasing prevalence of type 2 diabetes among younger age groups raises significant concern regarding future STEMI incidence in Egypt. Early identification of prediabetes, aggressive glycemic

control, weight management, and lifestyle modification are therefore essential components of cardiovascular prevention programs.[30]

Hypertension

Hypertension is one of the most prevalent cardiovascular risk factors worldwide and remains a major contributor to STEMI burden in Egypt. Chronic elevation of blood pressure promotes endothelial injury, vascular inflammation, arterial remodeling, left ventricular hypertrophy, and accelerated atherosclerosis. Hypertension also increases myocardial oxygen demand while simultaneously impairing coronary reserve, thereby enhancing susceptibility to myocardial ischemia.[31]

Globally, hypertension contributes to millions of cardiovascular deaths annually and represents one of the most important modifiable causes of stroke, heart failure, and ischemic heart disease. Epidemiological studies have demonstrated that even modest reductions in blood pressure significantly reduce cardiovascular mortality and adverse cardiovascular events. Consequently, hypertension control remains one of the most cost-effective interventions for cardiovascular disease prevention.[32]

Among STEMI patients, hypertension frequently coexists with diabetes, obesity, and dyslipidemia, creating a synergistic increase in cardiovascular risk. Egyptian studies have reported a high prevalence of hypertension among STEMI patients, particularly among older individuals. Poor awareness, inadequate treatment adherence, and suboptimal blood pressure control continue to contribute to residual cardiovascular risk despite availability of effective antihypertensive therapies.[21,33]

The growing prevalence of hypertension in Egypt is closely linked to urbanization, dietary sodium excess, obesity, physical inactivity, and aging of the population. Strengthening screening programs and improving long-term blood pressure control are therefore essential for reducing future STEMI incidence.[31]

Dyslipidemia

Dyslipidemia is a fundamental determinant of atherosclerotic cardiovascular disease and plays a central role in the development of STEMI. Elevated LDL-C promotes cholesterol deposition within the arterial wall, formation of foam cells, development of fatty streaks, and progression of atherosclerotic plaques. Conversely, reduced high-density lipoprotein cholesterol (HDL-C) impairs reverse cholesterol transport and diminishes vascular protection.[34]

Multiple lipid abnormalities contribute to cardiovascular risk, including elevated LDL-C, elevated triglycerides, increased lipoprotein(a), small dense LDL particles, and low HDL-C concentrations. Recent evidence suggests that residual cardiovascular risk persists even after substantial LDL-C reduction with statin therapy, highlighting the complexity of lipid-related risk and the importance of comprehensive lipid management.[35]

Egyptian STEMI patients frequently exhibit dyslipidemia, often in association with diabetes and metabolic syndrome. Elevated triglycerides and reduced HDL-C appear particularly common and may contribute to premature atherosclerosis. Current European guidelines recommend intensive lipid-lowering therapy targeting LDL-C levels below 55 mg/dL and at least 50% reduction from baseline among patients with acute coronary syndromes. Achievement of these targets remains essential for reducing recurrent cardiovascular events after STEMI.[36]

Emerging lipid biomarkers such as lipoprotein(a) have attracted increasing attention because of their association with premature myocardial infarction and residual cardiovascular risk. Future incorporation of advanced lipid profiling may improve cardiovascular risk stratification among Egyptian patients.[37]

Obesity, Physical Inactivity, and Metabolic Syndrome

Obesity has reached epidemic proportions worldwide and represents a major contributor to cardiovascular disease burden in Egypt. Excess adiposity promotes insulin resistance, dyslipidemia, hypertension, systemic inflammation, endothelial dysfunction, and prothrombotic states, all of which accelerate atherosclerosis and increase STEMI risk.[38]

Abdominal obesity is particularly important because visceral adipose tissue exhibits significant metabolic activity and contributes to chronic low-grade inflammation. Waist circumference and waist-to-hip ratio have emerged as powerful predictors of cardiovascular risk and may provide greater prognostic value than

body mass index alone.[39]

Physical inactivity further amplifies cardiovascular risk by worsening metabolic health, promoting obesity, and impairing vascular function. Regular physical activity improves blood pressure control, insulin sensitivity, endothelial function, lipid metabolism, inflammatory markers, and overall cardiovascular fitness. International guidelines recommend at least 150–300 minutes of moderate-intensity aerobic activity weekly to reduce cardiovascular risk.[40]

Metabolic syndrome represents the clustering of obesity, hypertension, dyslipidemia, and impaired glucose metabolism. This syndrome substantially increases the likelihood of coronary artery disease and acute myocardial infarction. The increasing prevalence of metabolic syndrome among Egyptians represents a major challenge for future cardiovascular disease prevention efforts.[41]

Family History and Genetic Predisposition

Family history of premature coronary artery disease is a well-established non-modifiable risk factor for STEMI. Individuals with first-degree relatives affected by premature coronary artery disease demonstrate significantly higher lifetime cardiovascular risk compared with those without such history. Family history reflects a complex interaction between genetic susceptibility and shared environmental influences.[42]

Several genetic polymorphisms have been implicated in cardiovascular risk, including variants affecting lipoprotein metabolism, inflammatory pathways, coagulation factors, and endothelial function. Although genetic testing is not routinely used in clinical practice, increasing understanding of genetic determinants may improve future risk stratification and personalized prevention strategies.[43]

In Egypt, family history frequently coexists with traditional cardiovascular risk factors, suggesting that inherited predisposition may amplify the adverse effects of smoking, diabetes, hypertension, and dyslipidemia. Comprehensive assessment of family history should therefore remain an integral component of cardiovascular risk evaluation.[42]

Emerging and Novel Cardiovascular Risk Factors

In addition to traditional risk factors, growing evidence supports the contribution of several emerging biomarkers and non-traditional factors to STEMI risk. Chronic inflammation has emerged as a critical component of atherosclerosis progression and plaque instability. High-sensitivity C-reactive protein (hs-CRP) is one of the most extensively studied inflammatory biomarkers and has demonstrated predictive value for myocardial infarction, stroke, and cardiovascular death.[44]

Elevated homocysteine levels have also been associated with endothelial dysfunction, oxidative stress, and increased thrombogenicity. Hyperhomocysteinemia may contribute to accelerated atherosclerosis and has been proposed as an independent cardiovascular risk factor in certain populations.[45]

Additional biomarkers including lipoprotein(a), fibrinogen, ferritin, interleukin-6, plasminogen activator inhibitor-1, and markers of oxidative stress have shown associations with coronary artery disease and acute myocardial infarction. While many of these biomarkers have not yet been incorporated into routine clinical practice, they may improve future risk prediction models and identify high-risk individuals who would benefit from targeted interventions.[37,46]

Psychological stress, depression, sleep disorders, chronic kidney disease, autoimmune diseases, and environmental exposures have also emerged as contributors to cardiovascular risk. These factors are increasingly recognized as important determinants of cardiovascular health and may partially explain residual cardiovascular risk not captured by traditional risk factor assessment.[47,48]

Overall, the cardiovascular risk profile of Egyptian STEMI patients is characterized by a high prevalence of modifiable risk factors, particularly smoking, diabetes mellitus, hypertension, dyslipidemia, obesity, and metabolic syndrome. These risk factors interact synergistically to promote premature atherosclerosis and acute coronary events. Consequently, comprehensive prevention strategies targeting both traditional and emerging risk factors remain essential for reducing STEMI incidence and improving cardiovascular outcomes in Egypt.

Pathophysiology of STEMI: From Atherosclerosis to Coronary Occlusion

Understanding the pathophysiology of ST-segment elevation myocardial infarction (STEMI) is

fundamental to appreciating the rationale behind contemporary prevention and treatment strategies. STEMI represents the final manifestation of a prolonged and complex biological process involving endothelial dysfunction, lipid accumulation, chronic vascular inflammation, atherosclerotic plaque formation, plaque destabilization, thrombosis, and ultimately complete coronary artery occlusion. Although acute coronary occlusion occurs abruptly, the underlying pathological process often evolves silently over several decades before becoming clinically evident.[49,50]

Endothelial Dysfunction: The Earliest Stage of Atherosclerosis

The vascular endothelium is a highly active organ that regulates vascular tone, platelet activity, inflammation, coagulation, and cellular adhesion. Under physiological conditions, endothelial cells maintain vascular homeostasis through production of nitric oxide (NO), prostacyclin, and other mediators that inhibit thrombosis and vascular inflammation. However, exposure to cardiovascular risk factors including smoking, hypertension, diabetes mellitus, dyslipidemia, obesity, and chronic inflammation results in endothelial dysfunction, which is considered the earliest detectable stage of atherosclerosis.[51]

Endothelial dysfunction is characterized by reduced nitric oxide bioavailability, increased oxidative stress, impaired vasodilation, enhanced expression of adhesion molecules, and increased vascular permeability. These changes facilitate migration of inflammatory cells into the arterial wall and promote lipid deposition within the intima. Importantly, endothelial dysfunction may precede visible atherosclerotic lesions by many years and predicts future cardiovascular events independently of traditional risk factors.[52]

One of the earliest molecular changes is increased expression of vascular cell adhesion molecule-1 (VCAM-1), intracellular adhesion molecule-1 (ICAM-1), and selectins, which facilitate recruitment and adhesion of circulating monocytes and T lymphocytes to the endothelium. These inflammatory cells subsequently migrate into the subendothelial space, initiating the inflammatory cascade that drives atherogenesis.[53]

Lipoprotein Retention and Formation of Fatty Streaks

The next critical step in atherosclerosis development involves accumulation of atherogenic lipoproteins, particularly low-density lipoprotein cholesterol (LDL-C), within the arterial intima. Once trapped within the vessel wall, LDL particles undergo oxidative modification through interactions with reactive oxygen species, macrophages, and vascular enzymes. Oxidized LDL possesses potent pro-inflammatory properties and serves as a major stimulus for further leukocyte recruitment and activation.[54]

Macrophages internalize oxidized LDL through scavenger receptors, transforming into lipid-laden foam cells. Progressive accumulation of foam cells creates the earliest visible atherosclerotic lesion known as the fatty streak. Although fatty streaks may be observed even in young individuals, progression to advanced atherosclerotic plaques depends on persistence of risk factors and ongoing vascular inflammation.[55]

Foam cells produce numerous cytokines, growth factors, and matrix-degrading enzymes that perpetuate inflammation and promote migration of vascular smooth muscle cells from the media into the intima. These smooth muscle cells contribute to extracellular matrix production and fibrous cap formation, which are hallmarks of mature atherosclerotic plaques.[50,56]

Chronic Vascular Inflammation and Plaque Progression

Modern understanding of atherosclerosis recognizes inflammation as a central driver of disease progression. Rather than being merely a disorder of cholesterol accumulation, atherosclerosis is now considered a chronic inflammatory disease of the arterial wall. Activated macrophages, T lymphocytes, endothelial cells, and smooth muscle cells participate in a complex network of inflammatory signaling pathways that regulate plaque growth and stability.[57]

Several cytokines play key roles in this process, including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and interferon-gamma. These mediators promote recruitment of additional inflammatory cells, stimulate smooth muscle proliferation, increase oxidative stress, and contribute to extracellular matrix degradation.[58]

The importance of inflammation in cardiovascular disease was highlighted by clinical studies demonstrating that inflammatory biomarkers such as high-sensitivity C-reactive protein (hs-CRP) predict future myocardial infarction independently of lipid levels. Furthermore, anti-inflammatory therapies targeting specific cytokine pathways have been shown to reduce cardiovascular events, providing direct evidence that inflammation contributes causally to atherosclerotic disease progression.[59]

Development of Vulnerable Atherosclerotic Plaques

As atherosclerotic plaques enlarge, their structural composition becomes increasingly important. Not all plaques possess equal risk for causing acute coronary syndromes. In fact, many severely stenotic plaques remain clinically stable, whereas less obstructive plaques may suddenly rupture and trigger STEMI.[60]

The concept of the "vulnerable plaque" has therefore become central to understanding acute coronary syndromes. Vulnerable plaques typically contain:

- A large lipid-rich necrotic core.
- Thin fibrous cap (<65 μm).
- Abundant inflammatory cell infiltration.
- Reduced smooth muscle cell content.
- Increased neovascularization.
- Elevated proteolytic enzyme activity.

These features collectively weaken plaque structural integrity and increase susceptibility to rupture under mechanical stress.[61]

Activated macrophages within vulnerable plaques secrete matrix metalloproteinases (MMPs), which degrade collagen and extracellular matrix components responsible for maintaining fibrous cap strength. Simultaneously, inflammatory cytokines inhibit collagen synthesis by smooth muscle cells, further destabilizing the plaque.[62]

Plaque Rupture and Plaque Erosion

Acute STEMI most commonly results from disruption of an atherosclerotic plaque. Two principal mechanisms have been identified: plaque rupture and plaque erosion.[63]

Plaque rupture accounts for approximately 60–75% of acute coronary syndromes. In plaque rupture, mechanical stress and inflammatory degradation cause the fibrous cap to fracture, exposing the highly thrombogenic lipid-rich core to circulating blood. This exposure triggers rapid platelet activation and thrombus formation.[64]

Plaque erosion represents an alternative mechanism responsible for approximately 25–40% of acute coronary syndromes. In this setting, endothelial denudation occurs without actual rupture of the fibrous cap. Platelets adhere directly to the exposed subendothelial surface, initiating thrombus formation. Plaque erosion is more frequently observed in younger individuals, smokers, and women.[63]

Although these mechanisms differ histologically, both ultimately result in acute coronary thrombosis and myocardial ischemia.[64]

Platelet Activation and Thrombus Formation

Following plaque disruption, exposure of collagen, tissue factor, von Willebrand factor, and other thrombogenic substances initiates platelet adhesion and activation. Platelets bind to exposed collagen through glycoprotein receptors and rapidly undergo conformational changes that enhance their prothrombotic activity.[65]

Activated platelets release adenosine diphosphate (ADP), thromboxane A_2, serotonin, and numerous inflammatory mediators. These substances amplify platelet recruitment and aggregation while simultaneously inducing coronary vasoconstriction. Platelet activation also leads to expression of glycoprotein IIb/IIIa receptors, which mediate fibrinogen-dependent platelet cross-linking and formation of platelet-rich thrombi.[66]

This process explains why antiplatelet therapy forms the cornerstone of STEMI treatment and why early administration of aspirin and P2Y12 inhibitors significantly improves clinical outcomes.[4]

Activation of the Coagulation Cascade

In parallel with platelet activation, exposure of tissue factor initiates activation of the coagulation cascade. Tissue factor interacts with factor VIIa, leading to sequential activation of coagulation proteins and generation of thrombin.[67]

Thrombin plays a central role in STEMI pathogenesis because it:

- Converts fibrinogen into fibrin.
- Activates platelets.
- Enhances inflammatory signaling.
- Stabilizes thrombus architecture.

Progressive fibrin deposition transforms an initially platelet-rich thrombus into a dense fibrin-rich clot capable of producing complete coronary occlusion.[68]

The importance of coagulation activation explains the beneficial effects of anticoagulant therapies during acute coronary syndromes and PCI procedures.[4]

Coronary Occlusion and Myocardial Ischemia

Complete thrombotic occlusion of an epicardial coronary artery produces abrupt cessation of myocardial blood flow distal to the obstruction. Within seconds, aerobic metabolism ceases and myocardial oxygen deprivation develops. Cellular ATP production falls dramatically, impairing membrane ion pumps and intracellular calcium regulation.[69]

Early ischemic changes include:

- Loss of myocardial contractility.
- Metabolic acidosis.
- Cellular edema.
- Electrical instability.

If coronary blood flow is restored promptly, these changes remain reversible. However, prolonged ischemia leads to irreversible myocyte necrosis.[70]

The concept that "time is muscle" reflects the direct relationship between ischemic duration and infarct size. Consequently, rapid reperfusion remains the most important determinant of myocardial salvage and survival.[71]

Myocardial Necrosis and Infarct Expansion

Irreversible myocardial injury generally begins after approximately 20–30 minutes of severe ischemia and progresses from the subendocardium toward the epicardium in a wavefront pattern. Without reperfusion, transmural necrosis may develop within several hours, producing the classical pathological substrate of STEMI.[72]

Necrotic cardiomyocytes release intracellular biomarkers including cardiac troponins and creatine kinase-MB, which serve as diagnostic indicators of myocardial infarction. The extent of biomarker elevation correlates with infarct size and prognosis.[73]

Myocardial necrosis triggers a robust inflammatory response involving neutrophils, monocytes, macrophages, and cytokines. While this response is necessary for removal of dead tissue and subsequent healing, excessive inflammation may contribute to infarct expansion and adverse ventricular remodeling.[74]

Reperfusion Injury

Although restoration of coronary blood flow is essential for myocardial salvage, reperfusion itself may paradoxically contribute to additional injury. Reperfusion injury results from sudden restoration of oxygen and nutrients to previously ischemic myocardium, generating oxidative stress, calcium overload, mitochondrial dysfunction, endothelial injury, and inflammatory activation.[75]

Clinical manifestations of reperfusion injury include:

- Reperfusion arrhythmias.
- Myocardial stunning.
- Microvascular obstruction.
- No-reflow phenomenon.

Microvascular dysfunction may persist despite successful opening of the epicardial coronary artery and remains an important determinant of infarct size and long-term ventricular function.[76]

Contemporary Concepts: The NLRP3 Inflammasome and Targeted Anti-Inflammatory Therapy

Recent advances have identified the NLRP3 inflammasome as a critical regulator of vascular inflammation and acute myocardial injury. Activation of the NLRP3 pathway stimulates production of IL-1β and IL-18, amplifying inflammatory responses within atherosclerotic plaques and ischemic myocardium.[77]

Subsequent activation of IL-6 signaling promotes hepatic synthesis of CRP and further propagates systemic inflammation. These discoveries have transformed understanding of cardiovascular disease and opened new therapeutic avenues targeting inflammatory pathways.[78]

The landmark CANTOS trial demonstrated that inhibition of IL-1β with canakinumab significantly reduced recurrent cardiovascular events independent of lipid lowering, providing direct proof that targeting inflammation can improve cardiovascular outcomes. Similarly, emerging evidence suggests potential benefits from therapies targeting IL-6 and other inflammatory mediators.[79]

These findings support the concept that STEMI represents not only a thrombotic event but also the culmination of chronic inflammatory processes operating throughout the natural history of atherosclerosis.[80]

In summary, STEMI develops through a complex sequence of events beginning with endothelial dysfunction and progressing through lipid accumulation, chronic inflammation, plaque vulnerability, plaque disruption, thrombosis, coronary occlusion, and myocardial necrosis. Contemporary evidence increasingly highlights the pivotal role of inflammation throughout this process and provides new opportunities for prevention and therapeutic intervention.

Clinical Characteristics and Presentation of STEMI in Egypt

The clinical presentation of ST-segment elevation myocardial infarction (STEMI) reflects the complex interaction between patient demographics, cardiovascular risk factors, extent of myocardial ischemia, infarct location, and healthcare system characteristics. Understanding the clinical characteristics of Egyptian STEMI patients is particularly important because several studies have demonstrated significant differences between Egyptian populations and patients from Europe and North America. These differences influence diagnosis, treatment delays, reperfusion strategies, and ultimately clinical outcomes.[81,82]

Demographic Characteristics of Egyptian STEMI Patients

One of the most consistent observations across Egyptian cardiovascular registries is the relatively young age at STEMI presentation. Compared with patients from many Western countries, Egyptian patients frequently develop acute myocardial infarction approximately 5–10 years earlier. This earlier presentation reflects the high prevalence of smoking, diabetes mellitus, metabolic syndrome, obesity, and other modifiable cardiovascular risk factors that accelerate atherosclerotic disease progression.[20,81]

The Egyptian Society of Cardiology STEMI registry demonstrated that Egyptian STEMI patients were significantly younger than those enrolled from other European Society of Cardiology (ESC) member countries. Premature myocardial infarction has important clinical and socioeconomic implications because it affects individuals during their most productive years, resulting in long-term disability, reduced quality of life, and increased healthcare expenditures.[20]

Male predominance remains a characteristic feature of STEMI populations worldwide and is similarly observed in Egypt. Men generally experience myocardial infarction at younger ages than women, partly due to higher smoking prevalence and the protective effects of endogenous estrogen before menopause. However, women presenting with STEMI often exhibit a greater burden of comorbidities, delayed presentation, and higher mortality rates compared with men.[83]

Symptomatology and Clinical Presentation

The hallmark symptom of STEMI is acute chest pain or chest discomfort resulting from prolonged myocardial ischemia. Typically, patients describe a retrosternal sensation of pressure, heaviness, squeezing, constriction, or burning that persists for more than 20–30 minutes and is not relieved by rest. Pain frequently radiates to the left arm, both arms, shoulders, neck, jaw, or back. Associated symptoms

commonly include diaphoresis, nausea, vomiting, dyspnea, palpitations, dizziness, and anxiety.[84]

Despite the classical description, clinical presentation varies considerably among patients. Several studies have demonstrated that a substantial proportion of STEMI patients present with atypical symptoms. Elderly individuals, women, and patients with diabetes mellitus are particularly prone to atypical presentations including unexplained fatigue, dyspnea, syncope, nausea, vomiting, abdominal discomfort, confusion, or generalized weakness.[85]

This observation is especially relevant in Egypt because diabetes mellitus is highly prevalent among STEMI patients. Diabetic autonomic neuropathy may blunt ischemic pain perception, resulting in delayed recognition of symptoms and postponement of medical evaluation. Consequently, diabetic patients often present later and may experience larger infarcts and worse outcomes.[86]

Importantly, absence of chest pain does not exclude STEMI. Studies have shown that a considerable proportion of patients with acute myocardial infarction present without classical chest discomfort. Such presentations are associated with delayed diagnosis, reduced likelihood of reperfusion therapy, and increased mortality.[85]

Symptom-to-Door Time and Healthcare-Seeking Behavior

One of the most important clinical characteristics influencing STEMI outcomes in Egypt is prolonged symptom-to-door time. The concept of total ischemic time encompasses the interval between symptom onset and successful reperfusion. Numerous studies have demonstrated that shorter ischemic times are associated with smaller infarct size, improved ventricular function, and reduced mortality.[87]

Unfortunately, delayed presentation remains common among Egyptian STEMI patients. Several factors contribute to this phenomenon, including limited public awareness regarding myocardial infarction symptoms, socioeconomic barriers, transportation difficulties, fear of hospitalization, and underutilization of emergency medical services. Many patients initially attribute symptoms to gastrointestinal or musculoskeletal causes, delaying medical consultation.[20]

Registry data indicate that Egyptian patients frequently present directly to hospitals through self-transport rather than activating ambulance services. This contrasts markedly with healthcare systems in Europe and North America where emergency medical services play a central role in STEMI triage and early management. Delayed presentation remains one of the major obstacles to optimal STEMI care in Egypt and contributes significantly to adverse clinical outcomes.[20,88]

Physical Examination Findings and Hemodynamic Status

Clinical examination remains an important component of STEMI assessment and provides valuable prognostic information. Although some patients appear hemodynamically stable, others present with varying degrees of heart failure, cardiogenic shock, arrhythmias, or mechanical complications.[89]

The Killip classification remains one of the most widely used clinical tools for risk stratification following STEMI:

- Killip Class I: No evidence of heart failure.
- Killip Class II: Mild heart failure with pulmonary congestion or S3 gallop.
- Killip Class III: Acute pulmonary edema.
- Killip Class IV: Cardiogenic shock.

Higher Killip class at presentation is strongly associated with increased short-term and long-term mortality. Most STEMI patients present in Killip class I; however, patients presenting with cardiogenic shock continue to experience extremely high mortality despite contemporary reperfusion therapies.[90]

Hypotension, tachycardia, elevated jugular venous pressure, pulmonary rales, and peripheral hypoperfusion indicate more extensive myocardial injury and should prompt urgent hemodynamic assessment and aggressive management.[89]

Electrocardiographic Characteristics

The electrocardiogram (ECG) remains the cornerstone of STEMI diagnosis and should be performed within 10 minutes of first medical contact according to contemporary guidelines. STEMI is characterized by new ST-segment elevation in anatomically contiguous leads reflecting transmural myocardial ischemia

secondary to acute coronary occlusion.[4]

Typical ECG findings include:

- ST-segment elevation at the J-point.
- Hyperacute T waves.
- Reciprocal ST-segment depression.
- Development of pathological Q waves.
- Progressive T-wave inversion during evolution of infarction.

The location of ST-segment elevation provides important information regarding infarct territory and culprit vessel.[91]

Anterior STEMI, usually resulting from left anterior descending artery occlusion, generally carries the worst prognosis because of the large myocardial territory involved. Inferior STEMI is commonly associated with right coronary artery occlusion and may be complicated by bradyarrhythmias and right ventricular infarction. Lateral and posterior infarctions are less common but require careful recognition because their ECG manifestations may be subtle.[92]

Several Egyptian studies have reported anterior wall myocardial infarction as the most common STEMI subtype, consistent with international observations. Because anterior infarctions often involve larger myocardial territories, they are associated with higher rates of left ventricular dysfunction, heart failure, and mortality.[93]

Laboratory Characteristics

Cardiac biomarkers play a crucial role in confirming myocardial injury. High-sensitivity cardiac troponin (hs-cTn) has become the preferred biomarker because of its superior sensitivity and specificity for myocardial necrosis.[4]

Following coronary occlusion, troponin levels begin to rise within a few hours, peak during the first 24 hours, and may remain elevated for several days. The magnitude of troponin elevation often correlates with infarct size and clinical prognosis.[94]

Additional laboratory abnormalities frequently observed among STEMI patients include:

- Hyperglycemia.
- Elevated inflammatory markers.
- Leukocytosis.
- Elevated serum creatinine.
- Dyslipidemia.
- Elevated natriuretic peptides.

Admission hyperglycemia has been associated with increased mortality even among non-diabetic patients and may reflect heightened neurohormonal and inflammatory activation during acute myocardial infarction.[95]

Inflammatory biomarkers such as C-reactive protein (CRP), interleukin-6, and leukocyte counts may also provide prognostic information regarding infarct size, ventricular remodeling, and future cardiovascular events.[96]

Echocardiographic Characteristics

Transthoracic echocardiography represents an essential imaging modality in STEMI evaluation and should be performed routinely during hospitalization. Echocardiography provides rapid assessment of ventricular function, infarct extent, mechanical complications, and alternative diagnoses.[4]

The most common echocardiographic findings include:

- Regional wall motion abnormalities.
- Reduced left ventricular ejection fraction (LVEF).
- Left ventricular dilatation.
- Mitral regurgitation.
- Right ventricular dysfunction.
- Pericardial effusion.

Left ventricular ejection fraction remains one of the strongest predictors of mortality following STEMI. Patients with severe systolic dysfunction are at increased risk of heart failure, ventricular arrhythmias, sudden cardiac death, and adverse ventricular remodeling.[97]

Echocardiography also plays a critical role in identifying mechanical complications such as ventricular septal rupture, papillary muscle rupture, and free-wall rupture, which require urgent intervention and are associated with high mortality.[98]

Coronary Angiographic Characteristics

Coronary angiography remains the gold standard for identifying culprit lesions and guiding reperfusion therapy. Contemporary studies indicate that STEMI most commonly results from acute thrombotic occlusion of a single epicardial coronary artery, although multivessel disease is frequently present.[99]

Among Egyptian STEMI patients, angiographic findings generally mirror international observations. The left anterior descending artery is most frequently identified as the culprit vessel, followed by the right coronary artery and left circumflex artery. Multivessel coronary disease is particularly common among diabetic patients and those with metabolic syndrome.[100]

The extent of coronary artery disease significantly influences prognosis. Patients with multivessel disease experience higher rates of recurrent ischemia, heart failure, and long-term mortality compared with those having single-vessel disease.[99]

Egyptian Registry Findings and Contemporary Clinical Profile

The Egyptian Society of Cardiology STEMI registry provided the most comprehensive contemporary assessment of STEMI characteristics in Egypt. Several notable findings emerged:

- Egyptian patients were younger than their European counterparts.
- Smoking prevalence was significantly higher.
- Diabetes mellitus was more common.
- Delays from symptom onset to hospital presentation were longer.
- Self-presentation predominated over ambulance transport.
- Primary PCI utilization was lower than in many ESC countries.
- In-hospital mortality was highest among patients who did not receive reperfusion therapy.[20]

These observations emphasize the unique clinical profile of STEMI in Egypt and underscore the importance of public education, risk factor modification, expansion of primary PCI networks, and improved emergency medical systems. Addressing these challenges may substantially improve outcomes and reduce the growing burden of STEMI nationwide.[20,88]

Overall, Egyptian STEMI patients exhibit distinctive demographic and clinical characteristics characterized by younger age at presentation, a high burden of modifiable cardiovascular risk factors, delayed hospital arrival, and variable access to reperfusion therapy. Recognition of these characteristics is essential for developing targeted interventions aimed at improving diagnosis, treatment, and cardiovascular outcomes throughout Egypt.

Conclusion

ST-segment elevation myocardial infarction (STEMI) continues to represent a major cardiovascular health challenge in Egypt, characterized by a relatively young age at presentation, a high prevalence of modifiable risk factors—particularly smoking and diabetes mellitus—and persistent delays in accessing definitive reperfusion therapy. Contemporary evidence indicates that although substantial progress has been achieved through expansion of primary percutaneous coronary intervention services and implementation of guideline-directed therapies, significant gaps remain in public awareness, emergency medical service utilization, timely diagnosis, and equitable access to advanced cardiovascular care. The distinctive epidemiological and clinical profile of Egyptian STEMI patients highlights the need for population-specific prevention and management strategies. Strengthening cardiovascular risk factor control, promoting early symptom recognition, expanding regional STEMI networks, improving prehospital systems of care, and ensuring broader availability of evidence-based reperfusion therapies are essential steps toward reducing STEMI-related morbidity and mortality. Future national initiatives integrating

prevention, rapid reperfusion, secondary prevention, and cardiac rehabilitation have the potential to substantially improve cardiovascular outcomes and lessen the growing burden of ischemic heart disease in Egypt.

References

1. Joseph P, Leong D, McKee M, et al. Reducing the global burden of cardiovascular disease. *Circ Res*. 2017;121(6):677-694.
2. World Health Organization. Cardiovascular diseases fact sheet. World Health Organization.
3. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction. *Eur Heart J*. 2019;40(3):237-269.
4. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. *Eur Heart J*. 2023;44(38):3720-3826.
5. Shaheen SM, ElGuindy AM, Elhadidy A, et al. Characteristics, management, and outcomes of STEMI patients in Egypt compared with ESC countries. *Eur Heart J Acute Cardiovasc Care*. 2020.
6. Townsend N, Wilson L, Bhatnagar P, et al. Cardiovascular disease in Europe: epidemiological update 2016. *Eur Heart J*. 2016;37(42):3232-3245.
7. Wang H, Naghavi M, Allen C, et al. Global, regional, and national life expectancy and cause-specific mortality. *Lancet*. 2016;388(10053):1459-1544.
8. Ralapanawa U, Kumarasiri PVR, Jayawickreme KP, et al. Epidemiology and risk factors of acute coronary syndrome. *Int J Cardiol Heart Vasc*. 2019;22:1-8.
9. Kazi DS, Penko J, Bibbins-Domingo K. Trends in cardiovascular risk factors among STEMI patients. *J Am Heart Assoc*. 2023.
10. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in people with diabetes. *Lancet*. 2006;368(9529):29-36.
11. Laaksonen DE, Lakka HM, Niskanen LK, et al. Metabolic syndrome and cardiovascular disease risk. *Am J Cardiol*. 2002;89(6):509-512.
12. Abera A, Worede A, Hirigo AT, Alemayehu R, Ambachew S. Dyslipidemia and associated factors among adult cardiac patients. *Eur J Med Res*. 2024;29(1).
13. Huang PL. A comprehensive definition for metabolic syndrome. *Dis Model Mech*. 2009;2(5-6):231-237.
14. Onor IO, Stirling DL, Williams SR, et al. Clinical effects of cigarette smoking. *Int J Environ Res Public Health*. 2017;14(10):1147.
15. Hbejan K. Smoking effect on ischemic heart disease in young patients. *Heart Views*. 2011;12(1):1-6.
16. Kenfield SA, Stampfer MJ, Rosner BA, Colditz GA. Smoking cessation and coronary heart disease risk. *JAMA*. 2010;303(19):1911-1919.
17. Hu FB, Stampfer MJ, Solomon CG, et al. Diabetes mellitus and cardiovascular disease risk. *Arch Intern Med*. 2002;162(22):2597-2604.
18. Lawes CMM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease. *Lancet*. 2008;371(9623):1513-1518.
19. Ng M, Fleming T, Robinson M, et al. Global prevalence of overweight and obesity. *Lancet*. 2014;384(9945):766-781.
20. Ades PA, Savage PD. Obesity in coronary heart disease. *Prev Med*. 2017;104:117-119.
21. Alves AJ, Viana JL, Cavalcante SL, et al. Physical activity in cardiovascular disease prevention. *World J Cardiol*. 2016;8(10):575-583.
22. Osadnik T, Reguła R, Fronczek M, et al. Family history and cardiovascular mortality. *Atherosclerosis*. 2018;271:81-87.
23. Vernon ST, Coffey S, D'Souza M, et al. Genetic determinants of coronary artery disease. *Heart Lung Circ*. 2019;28(1):1-15.
24. Polyakova EA, Mikhaylov VA. High-sensitivity C-reactive protein and cardiovascular disease. *Kardiologiia*. 2020;60(5):87-95.
25. Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): a genetically determined cardiovascular risk factor. *J Am Coll Cardiol*. 2022;79(22):2230-2248.
26. Libby P. The changing landscape of atherosclerosis. *Nature*. 2021;592(7855):524-533.
27. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction and cardiovascular disease. *Arterioscler Thromb Vasc Biol*. 2003;23(2):168-175.
28. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction. *Circulation*. 2007;115(10):1285-1295.
29. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. *Circulation*. 2002;105(9):1135-1143.
30. Ross R. Atherosclerosis—an inflammatory disease. *N Engl J Med*. 1999;340(2):115-126.
31. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med*. 2005;352(16):1685-1695.
32. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab. *N Engl J Med*. 2017;377(12):1119-1131.
33. Kolodgie FD, Virmani R, Burke AP, et al. Pathologic assessment of the vulnerable plaque. *Arterioscler Thromb Vasc Biol*.

2004;24(8):e43-e45.

34. Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable plaque. *Arterioscler Thromb Vasc Biol*. 2010;30(7):1282-1292.
35. Libby P, Pasterkamp G, Crea F, Jang IK. Reassessing acute coronary syndrome mechanisms. *Eur Heart J*. 2022;43(30):2914-2931.
36. Jackson SP. Arterial thrombosis. *Nat Med*. 2011;17(11):1423-1436.
37. Mackman N. Role of tissue factor in thrombosis. *Blood Cells Mol Dis*. 2006;36(2):104-107.
38. Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury. *N Engl J Med*. 2013;369(18):1722-1734.
39. Frangogiannis NG. Regulation of the inflammatory response in myocardial infarction. *Circ Res*. 2012;110(1):159-173.
40. Toldo S, Abbate A. The NLRP3 inflammasome in acute myocardial infarction. *Circ Res*. 2018;122(10):159-171.
41. Nakao T, Libby P. Interleukin-6 and atherosclerotic cardiovascular disease. *Eur Heart J*. 2023;44(5):457-469.
42. Chandrasekhar J, Gill A, Mehran R. Acute myocardial infarction in women. *Curr Atheroscler Rep*. 2018;20(8).
43. Widimsky P, Wijns W, Fajadet J, et al. Reperfusion therapy and STEMI systems of care. *Eur Heart J*. 2014;35(15):949-957.
44. Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit. *Am J Cardiol*. 1967;20(4):457-464.
45. Birnbaum Y, Drew BJ. ECG diagnosis of acute myocardial infarction. *Circulation*. 2003;107(25):324-326.
46. Collinson PO, Gaze DC. Biomarkers of myocardial injury. *Ann Clin Biochem*. 2007;44(Pt 1):1-13.
47. Greaves K. Role of echocardiography in acute myocardial infarction. *Heart*. 2002;88(4):419-425.
48. Figueras J, Alcalde O, Barrabés JA, et al. Mechanical complications after STEMI. *Eur Heart J Acute Cardiovasc Care*. 2020;9(Suppl):S86-S95.
49. Faxon DP, Fuster V, Libby P, et al. Atherosclerotic vascular disease conference: pathophysiology. *Circulation*. 2004;109(21):2617-2625.
50. Du XM, Kim MJ, Hou L, et al. Oxidized LDL and atherosclerosis. *Clin Sci*. 2015;129(4):311-324.
51. Geng YJ, Libby P. Progression of atherosclerotic plaques. *Cardiovasc Res*. 2002;54(3):502-510.
52. Ridker PM. Inflammatory biomarkers and cardiovascular risk. *Circ Res*. 2014;114(4):594-595.
53. Ambrose JA, Winters SL, Arora RR, et al. Coronary angiographic morphology in myocardial infarction. *J Am Coll Cardiol*. 1985;6(6):1233-1238.
54. Davies MJ. Stability and instability of coronary plaques. *Circulation*. 1996;94(8):2013-2020.
55. Massberg S, Brand K, Grüner S, et al. Platelet adhesion and thrombus formation. *J Exp Med*. 2002;196(7):887-896.
56. Hoffman M, Monroe DM. Coagulation cascade revisited. *Thromb Haemost*. 2001;85(6):958-965.
57. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. Wavefront phenomenon of ischemic cell death. *Circulation*. 1977;56(5):786-794.
58. Jennings RB, Sommers HM, Smyth GA, et al. Myocardial necrosis induced by temporary ischemia. *Arch Pathol*. 1960;70:68-78.
59. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. *N Engl J Med*. 2007;357(11):1121-1135.
60. Niccoli G, Scalone G, Lerman A, Crea F. Coronary microvascular obstruction in acute myocardial infarction. *Eur Heart J*. 2016;37(13):1024-1033.
61. Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1. *Circ Res*. 2016;118(1):145-156.
62. Libby P. Molecular mechanisms of thrombotic complications of atherosclerosis. *J Intern Med*. 2008;263(5):517-527.
63. Elendu C, Amaechi DC, Ajao O, et al. Global epidemiology and burden of STEMI. *Cureus*. 2023;15.
64. Agarwal S, Sharma A, Agarwal A. Risk of myocardial infarction in young adults. *J Adv Med Dent Sci Res*. 2014;2.
65. Kosiborod M, Rathore SS, Inzucchi SE, et al. Admission glucose and mortality in acute myocardial infarction. *Circulation*. 2005;111(23):3078-3086.
66. Scirica BM, Morrow DA, Cannon CP, et al. Inflammatory biomarkers in acute coronary syndromes. *Circulation*. 2007;115(12):1521-1527.
67. Bob-Manuel T, Ifedili I, Reed G, Ibebuogu UN, Khouzam RN. Non-ST elevation acute coronary syndromes: comprehensive review. *Curr Probl Cardiol*. 2017;42(9):266-305.
68. Canto JG, Kiefe CI, Rogers WJ, et al. Number of coronary heart disease risk factors and mortality in myocardial infarction. *JAMA*. 2011;306(19):2120-2127.
69. Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in coronary heart disease. *JAMA*. 2003;290(7):898-904.
70. Shah B, Bangalore S, Gianos E, et al. Temporal trends in risk profiles of patients with myocardial infarction. *Am J Med*. 2014;127(10):942-949.
71. Shah N, Kelly AM, Cox N, Wong C, Soon K. Myocardial infarction in young adults. *Heart Lung Circ*. 2016;25(10):955-960.
72. Zhou Y. Serum ferritin and cardiovascular risk. *Front Cardiovasc Med*. 2024;11.
73. Ma J, Hennekens CH, Ridker PM, Stampfer MJ. Prospective study of fibrinogen and coronary heart disease. *J Am Coll Cardiol*.

1999;33(5):1347-1352.

74. Unadkat S, Shah K, Shah A. Hyperhomocysteinemia and cardiovascular disease. *Cureus*. 2024;16.
75. Paré G, Çaku A, McQueen M, et al. Lipoprotein(a) levels and risk of myocardial infarction. *J Am Coll Cardiol*. 2019;74(12):1520-1530.
76. Tofler GH, Massaro J, O'Donnell CJ, et al. Plasminogen activator inhibitor and cardiovascular disease. *J Thromb Haemost*. 2016;14(7):1429-1437.
77. Ridker PM, Pare G, Parker A, et al. Polymorphism in CETP gene and cardiovascular risk. *Circ Cardiovasc Genet*. 2009;2(1):26-33.
78. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in cardiometabolic risk. *Diabetes Care*. 2008;31(4):811-822.
79. Bahrami M, Barati H, Jahani MM, et al. Lipoprotein lipase gene variants and acute myocardial infarction. *Egypt J Med Hum Genet*. 2015;16(4):327-332.
80. Umeda M. Apolipoprotein gene polymorphisms and coronary artery disease. *J Atheroscler Thromb*. 2009.
81. Datta Chaudhuri R, et al. HIF1A gene and coronary artery disease. *Cardiovasc Res*. 2021.
82. Rosendaal FR, Siscovick DS, Schwartz SM, et al. Factor V Leiden and myocardial infarction. *Blood*. 1997;89(8):2817-2821.
83. Mallhi TH, et al. MTHFR polymorphism and cardiovascular disease. *Pharmgenomics Pers Med*. 2023.
84. Chen J, et al. Methionine synthase gene polymorphism and cardiovascular disease. *Circulation*. 2001.
85. Rezkalla SH, Kloner RA. Cocaine-induced acute myocardial infarction. *Clin Med Res*. 2007;5(3):172-176.
86. Goliasch G, et al. Decreased serum Wnt and cardiovascular risk. *Eur Heart J*. 2012.
87. Sakamoto M, et al. Gamma-glutamyl transferase and cardiovascular disease. *Atherosclerosis*. 2013.
88. Milazzo V, et al. Vitamin D and cardiovascular disease. *Nutrients*. 2017.
89. Yeap BB, et al. Osteocalcin and cardiovascular disease. *J Clin Endocrinol Metab*. 2015.
90. Arambam P, Gupta S, Kaul U, Ranjan P, Sekhawat S, Janardhanan R. Hypothyroidism in acute coronary syndrome. *Indian Heart J*. 2024;76(1):44-47.
91. Farooq V, et al. Systemic lupus erythematosus and cardiovascular disease. *J Am Coll Cardiol*. 2017.
92. Lindhardsen J, Ahlehoff O, Gislason GH, et al. Rheumatoid arthritis and myocardial infarction risk. *Ann Rheum Dis*. 2011;70(6):929-934.
93. Barbaro G. Heart and HAART: HIV-associated cardiology issues. *World J Cardiol*. 2010;2(3):53-63.
94. Serpytis P, et al. Kawasaki disease and myocardial infarction. *Medicina*. 2015;51(3):174-178.
95. Miller M, Cannon CP, Murphy SA, et al. Impact of triglycerides after acute coronary syndrome. *J Am Coll Cardiol*. 2008;51(7):724-730.
96. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin. *N Engl J Med*. 2005;352(14):1425-1435.
97. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for dyslipidemia management. *J Clin Lipidol*. 2015;9(2):129-169.
98. Budaj A, et al. Dyslipidemia and lipid-lowering therapy in coronary syndromes. *Eur Heart J Suppl*. 2024.
99. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease. *Circulation*. 2011;123(20):2292-2333.